As part of our ongoing aim to bring you reports of innovative developments, we have added a review of the IMpower010 trial; adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer.
Independent commentary is provided by Associate Professor Bryan Chan, a senior medical oncologist at Coastal Cancer Care, Sunshine Coast University Hospital and Griffith University in Queensland.
Please login below to download this issue (PDF)